Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors’ cases and published cases of eculiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Macia, Manuel, de Alvaro Moreno, Fernando, Dutt, Tina, Fehrman, Ingela, Hadaya, Karine, Gasteyger, Christoph, Heyne, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Hereditary Kidney Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466111/
https://www.ncbi.nlm.nih.gov/pubmed/28621343
http://dx.doi.org/10.1093/ckj/sfw115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466111/
https://www.ncbi.nlm.nih.gov/pubmed/28621343
http://dx.doi.org/10.1093/ckj/sfw115

Ejemplares similares